ibudilast and Alcohol Abuse studies

Research Excerpts

Excerpt	Relevance	Reference
" In this study, we examined the ability of ibudilast, a non-selective phosphodiesterase inhibitor, to reduce alcohol drinking and relapse in alcohol-preferring P rats, high-alcohol drinking HAD1 rats, and in mice made dependent on alcohol through cycles of alcohol vapor exposure."	7.81	Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. ( Becker, HC; Bell, RL; Cui, C; Egli, M; Franklin, KM; Johnson, KW; Lopez, MF, 2015)
"Ibudilast-treated participants had lower Cho in superior frontal white matter and nominally lower MI in pregenual anterior cingulate cortex."	7.11	Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial. ( Alger, J; Burnette, E; Evans, CJ; Grodin, EN; Irwin, MR; London, ED; Meredith, LR; Miotto, K; Nieto, SJ; O'Neill, J; Ray, LA, 2022)
"Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor and was recently found to reduce alcohol intake in rats by ∼50%."	6.84	Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial. ( Bujarski, S; Heinzerling, K; Miotto, K; Ray, LA; Roche, DJ; Shoptaw, S, 2017)
" In this study, we examined the ability of ibudilast, a non-selective phosphodiesterase inhibitor, to reduce alcohol drinking and relapse in alcohol-preferring P rats, high-alcohol drinking HAD1 rats, and in mice made dependent on alcohol through cycles of alcohol vapor exposure."	3.81	Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. ( Becker, HC; Bell, RL; Cui, C; Egli, M; Franklin, KM; Johnson, KW; Lopez, MF, 2015)
"Ibudilast-treated participants had lower Cho in superior frontal white matter and nominally lower MI in pregenual anterior cingulate cortex."	3.11	Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial. ( Alger, J; Burnette, E; Evans, CJ; Grodin, EN; Irwin, MR; London, ED; Meredith, LR; Miotto, K; Nieto, SJ; O'Neill, J; Ray, LA, 2022)
"Non-treatment-seeking participants (n = 45) with current alcohol use disorder were randomized to receive twice-daily dosing with either ibudilast (50 mg; n = 20) or placebo (n = 25)."	3.01	Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in alcohol use disorder. ( Burnette, EM; Grodin, EN; Irwin, MR; Ray, LA, 2021)
"Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor and was recently found to reduce alcohol intake in rats by ∼50%."	2.84	Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial. ( Bujarski, S; Heinzerling, K; Miotto, K; Ray, LA; Roche, DJ; Shoptaw, S, 2017)

Research

Studies (7)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Any Drinking

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (28.57)	24.3611
2020's	5 (71.43)	2.80

Authors	Studies
Burnette, EM	2
Ray, LA	6
Irwin, MR	3
Grodin, EN	5
Nieto, SJ	1
Meredith, LR	2
Burnette, E	2
O'Neill, J	1
Alger, J	1
London, ED	1
Miotto, K	4
Evans, CJ	1
Green, R	1
Chorpita, M	1
Baskerville, WA	1
Bujarski, S	2
Towns, B	1
Nieto, S	1
Lim, A	1
Lin, J	1
Gillis, A	1
Evans, C	1
Bell, RL	1
Lopez, MF	1
Cui, C	1
Egli, M	1
Johnson, KW	1
Franklin, KM	1
Becker, HC	1
Shoptaw, S	1
Roche, DJ	1
Heinzerling, K	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Withdrawal-Related Dysphoria as a Moderator of Ibudilast for Alcohol Use Disorder[NCT03489850]	Phase 2	52 participants (Actual)	Interventional	2018-07-16	Completed
Development of Ibudilast as a Novel Treatment for Alcohol Dependence[NCT02025998]	Phase 1	24 participants (Actual)	Interventional	2013-12-31	Completed
A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder[NCT03594435]	Phase 2	102 participants (Actual)	Interventional	2018-10-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Medication effects on number of days where any drinking was reported. . Values indicate estimated probability of a drinking day across time for each group. (NCT03489850)
Timeframe: 14 days

Heavy Drinking

Intervention	predicted probability in percent (Number)
Ibudilast	59.25
Placebo	63.63

Medication effects on number of heavy drinking days. Heavy drinking is defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as ≥5 drinks/day for men and ≥4 drinks/day for women. Values indicate estimated probability of a heavy drinking day across time for each group. (NCT03489850)
Timeframe: 14 days

Negative Affect

Intervention	predicted probability in percent (Number)
Ibudilast	24.16
Placebo	36.80

"Negative affect as measured by self-reported ratings of Downhearted, Discouraged, Uneasy, and Anxious. Each item was rated on a scale from 0 (not at all) to 4 (extremely). The 4 items were summed for the total negative affect score for each day, ranging from 0 - 16. Higher scores indicate more negative mood." (NCT03489850)
Timeframe: Assessed through daily prompts throughout the 2-week study period.

Ventral Striatum Activation

Intervention	units (Least Squares Mean)
Ibudilast	2.91
Placebo	2.47

Medication effect on alcohol cue-induced ventral striatal activation. Participants completed an fMRI alcohol cue-reactivity paradigm where they viewed pictures of alcoholic beverages, non-alcoholic beverages, blurred images, and a plus sign. The mean percent signal change between the ALC and BEV blocks was extracted from an a priori defined region of interest: bilateral ventral striatum (VS), 6 mm-radius sphere centered at ±12 6 9 in MNI space. (NCT03489850)
Timeframe: Day 8

Article	Year
Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in alcohol use disorder. Alcoholism, clinical and experimental research, 2021, Volume: 45, Issue:10 Topics: Adult; Alcoholism; Brain; Connectome; Female; Humans; Magnetic Resonance Imaging; Male; Phosphodiest	2021
Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial. Addiction biology, 2022, Volume: 27, Issue:4 Topics: Alcohol Drinking; Alcoholism; Animals; Aspartic Acid; C-Reactive Protein; Choline; Creatine; Humans;	2022
Ibudilast moderates the effect of mood on alcohol craving during stress exposure. Experimental and clinical psychopharmacology, 2022, Volume: 30, Issue:5 Topics: Affect; Alcohol Drinking; Alcoholism; Craving; Ethanol; Humans; Indolizines; Pyrazoles; Pyridines	2022
Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial. Trials, 2020, Sep-11, Volume: 21, Issue:1 Topics: Alcohol Drinking; Alcoholism; Clinical Trials, Phase II as Topic; Craving; Double-Blind Method; Fema	2020
Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial. Translational psychiatry, 2021, 06-12, Volume: 11, Issue:1 Topics: Alcohol Drinking; Alcoholism; Craving; Cues; Humans; Magnetic Resonance Imaging; Pyridines	2021
Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017, Volume: 42, Issue:9 Topics: Adult; Affect; Alcohol Deterrents; Alcoholism; Central Nervous System Depressants; Craving; Cross-Ov	2017

ibudilast and Alcohol Abuse